CAR-T cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.
Han-Ning LiXiang ZhouGe WangDongyu HuaShuyu LiTao XuMenglu DongXiaoqing CuiXue YangYonglin WuMiaomiao CaiXinghua LiaoTongcun ZhangZhifang YangYa-Ying DuXingrui LiPublished in: The Journal of clinical endocrinology and metabolism (2021)
TSHR is a latent target antigen of CAR-T therapy for DTC. Anti-TSHR CAR-T could represent a therapeutic option for patients with local-regional relapsed or distant metastases of thyroid cancer and should be tested in carefully designed clinical trials.
Keyphrases
- clinical trial
- induced apoptosis
- cell cycle arrest
- acute lymphoblastic leukemia
- acute myeloid leukemia
- diffuse large b cell lymphoma
- lymph node
- multiple myeloma
- hodgkin lymphoma
- cell therapy
- endoplasmic reticulum stress
- cancer therapy
- stem cells
- signaling pathway
- randomized controlled trial
- cell death
- phase ii
- study protocol
- phase iii